SUZHOU, China, July 30,
2024 /PRNewswire/ -- On July
29, 2024, Porton Advanced Solutions ("Porton Advanced")
announced that it had reached a strategic cooperation with
Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both
sides will combine their respective strengths in the field of gene
therapy to jointly provide better drug development services.
Leveraging Porton Advanced's end-to-end cell and gene therapy CDMO
service platform and resource advantages, combined with Geneseed
Biotech's comprehensive core patented technologies in circRNA drug
concept validation and process development, the two companies will
jointly propel technological innovation and clinical translation,
thereby accelerating the implementation of innovative circRNA
therapies.
Proton Advanced is committed to providing end-to-end CDMO
services for cell and gene therapy, and has extensive experience in
nucleic acid therapy process development and GMP production,
covering various types including mRNA, saRNA, circRNA, and more.
Porton Advanced can provide comprehensive CMC services from
preclinical to clinical production. Geneseed Biotech, relying on
its profound technology and robust original R&D capability, has
broken through the technical bottleneck of circRNA drug development
and possesses independent intellectual property rights over its
core circularization technology. In this cooperation, both parties
will establish a comprehensive strategic partnership to deeply
expanding technological cooperation and resource sharing in the
field of circRNA. This will further strengthen Porton Advanced's
end-to-end CDMO platform, from innovation in research and
technology to high-quality project delivery, thereby providing more
valuable services to customers.
"We are very pleased to have entered into a strategic
collaboration with Porton Advanced." said Liu Ming, founder and CEO of Geneseed Biotech.
"CircRNA is recognized by the industry to be the next-generation
RNA platform for vaccines, rare disease therapies, and anti-tumor
therapies due to its high stability, low immunogenicity and
cost-effective production in drug development. As a pioneering
leader in circular RNA research and development, Geneseed Biotech
has consistently delved deep into this area, ranging from
scientific research to drug development, catering to the evolving
demands of our customers. Porton Advanced possesses extensive
service experience and profound technical expertise in CGT. Our
collaboration across the industrial chain can fully leverage each
other's professional and resource strengths, facilitating the
development of circRNA drugs and accelerating the industrialization
of circRNA technology."
"Collaborating with upstream and downstream enterprises across
the industrial chain to realize win-win cooperation and deliver
more valuable services to our customers is the core significance of
Porton Advanced's efforts in constructing a vibrant CGT ecosystem."
said Chen Hui, CFO of Porton
Advanced. "We are delighted to forge a strategic partnership with
Geneseed Biotech, an excellent CRO enterprise. Geneseed Biotech
possesses robust and innovative RNA synthesis technologies, coupled
with extensive project experience and platform advantages in the
scientific research and application translation of circRNA. By
integrating our respective technological strengths and platform
resources, we aim to further refine and enhance platform
capabilities of Porton Advanced, providing comprehensive CRDMO
solutions for the development of innovative RNA therapeutics from
early-stage research to clinical and commercial production,
empowering our global customers."
About Porton Advanced
Founded in 2018, Porton Advanced is a subsidiary of the globally
recognized CDMO Porton Pharma Solutions Ltd. (SZSE Stock Code
300363). Located in Suzhou, China, Porton Advanced offers a
cGMP-compliant manufacturing platform for plasmids, cell therapy,
gene therapy, and mRNA therapy, enabling different development
stages for global companies.
Porton Advanced operates on a "Customer First" approach to cell
and gene therapy (CGT) manufacturing, anchored by its core
principles of "Compliance, Expertise, and Open Collaboration". The
company operates to rigorous, internationally harmonized Quality
Management and IP protection standards, bringing innovative
manufacturing solutions to the complex challenges in the CGT space.
For more information about Porton Advanced, please
visit: www.portonadvanced.com.
About Geneseed Biotech
Guangzhou Geneseed Biotech. Co.,Ltd., founded in June 2010 and headquartered in Guangzhou Science
City, is a pioneer in circRNA scientific research and application
transformation. Geneseed is firmly grounded in robust and reliable
RNA synthesis innovation technology, consistently empowering
subdivisions from bench to bedside. Geneseed has broken through the
technical bottleneck of circRNA drug development and independently
developed two RNA circularization strategies --circPrecise® (based
on Group I intron self-splicing) & circPure® (based on T4
Rnl2). Relying on the original research and development capability,
Geneseed has established multiple technology platforms -- gene
synthesis, raw material synthesis, high-throughput sequencing, and
bioinformatics analysis, which can provide one-stop services
covering drug screening, sequence design, process development,
analytical method development, large-scale production, quality
control, and raw material preparation. Geneseed is committed to
providing biopharma with full-process solution CRDMO solution from
early R&D to commercial production. For more information about
Geneseed Biotech, please visit: www.geneseed.com.cn/en/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/porton-advanced-and-geneseed-biotech-enter-into-strategic-collaboration-to-focus-on-advancing-circrna-innovative-therapeutics-302209884.html
SOURCE Porton Advanced Solutions